Inside the research
BioLife Solutions, Inc.
BLFS Research profile · latest available data
Price overview
$38.49
▼ -0.09 (-0.2%)
| 52w hi | $38.58 |
|---|---|
| 52w lo | $18.15 |
| Vol | 998.50K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.40
| Short | +0.32 |
|---|---|
| Medium | +0.54 |
| Long | +0.30 |
computed 2026-09-27
Key fundamentals
BioLife Solutions, Inc.
Healthcare · Medical Instruments & Supplies
| Market cap | $1.88B |
|---|---|
| Enterprise value | $1.82B |
| Trailing P/E | 38.49x |
| Forward P/E | 116.64x |
| EV / EBITDA | 263.15x |
| P / S (ttm) | 17.65x |
| Profit margin | 54.3% |
| Return on equity | 12.8% |
| Revenue growth | +21.5% |
| Debt / equity | 3.75 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.20 | |
| Sector | +0.08 | |
| Technical | +0.33 | |
| Earnings | +0.00 | |
| Sentiment | -0.12 |
macro × 1.00 · 2026-09-27
Business overview
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Risk Metrics
| Beta vs SPX | 1.33 |
|---|---|
| Corr SPX | 0.44 |
| Annual vol | 49.0% |
| Annual ret | +32.0% |
| Sharpe | 0.65 |
| Max DD | -37.0% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-08-03 | Reg FD Disclosure, Exhibits | read |
| 2026-07-22 | Material Agreement, Reg FD Disclosure… | read |
| 2026-06-03 | Reg FD Disclosure, Exhibits | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-03-02 | Reg FD Disclosure, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2026-01-12 | Earnings Release, Exhibits | read |
| 2026-01-09 | Officer / Director Change | read |
| 2025-11-17 | Reg FD Disclosure, Exhibits | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-08-21 | Shareholder Vote | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 99.6% |
| HHI | 2,578 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $46.77M | 1.66M |
| Fidelity / FMR LLC | $28.05M | 993.11K |
| Capital Research / Capital World | $23.50M | 832.14K |
| Millennium Management | $19.08M | 675.66K |
| Citadel Advisors | $5.47M | 193.74K |
| AQR Capital Management | $444.47K | 15.74K |
| T. Rowe Price Group | $1.29K | 45.71K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $8.23M | +25.7% | |
| Gross profit | $62.12M | +60.6% | |
| Operating income | -$16.60M | -96.2% | |
| Net income | -$68.00M | -25.6% | |
| Cash from ops | -$12.50M | +67.0% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $38.51 | $38.68 | $38.12 | $38.49 | 998.50K |
| Sep 24 | $37.63 | $38.89 | $37.63 | $38.58 | 1.12M |
| Sep 23 | $38.04 | $38.39 | $37.32 | $37.74 | 929.70K |
| Sep 22 | $37.43 | $38.28 | $37.15 | $38.07 | 825.00K |
| Sep 21 | $36.70 | $37.36 | $36.53 | $37.18 | 406.60K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →